FOXP3 is essential for the development of natural CD4+/CD25+ Tregs in humans,19 although it also characterises CD4 + Tregs independently of CD25 expression.20 Under normal conditions, circulating Tregs represent 5% of the total CD4+ lymphocytic population, while their presence increases in cancer patients.21 Here, FOXP3 is linked to cancer.